GFM
DNLI icon

GF Fund Management’s Denali Therapeutics DNLI Stock Holding History

GF Fund Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.3K Buy
3,357
+63
+2% +$1.29K ﹤0.01% 346
2026
Q1 		$63.2K Buy
3,294
+413
+14% +$8.22K ﹤0.01% 377
2025
Q4 		$47.6K Sell
2,881
-265
-8% -$4.47K ﹤0.01% 410
2025
Q3 		$45.7K Sell
3,146
-539
-15% -$7.75K ﹤0.01% 402
2025
Q2 		$51.6K Hold
3,685
– – ﹤0.01% 411
2025
Q1 		$50.1K Buy
3,685
+663
+22% +$12.7K ﹤0.01% 421
2024
Q4 		$61.6K Buy
+3,022
New +$77.4K ﹤0.01% 369

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's DNLI Position: Q2 2026 in Review

GF Fund Management increased its Denali Therapeutics (DNLI) stake by 1.9% in Q2 2026, buying an estimated $1.29K and bringing the position to 3,357 shares worth $86.3K. The position accounts for ﹤0.01% of the portfolio, ranked #346.

GF Fund Management first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • GF Fund Management held 3,357 shares of Denali Therapeutics worth $86.3K as of Q2 2026.
  • GF Fund Management bought 63 Denali Therapeutics shares in Q2 2026, an estimated $1.29K.
  • Denali Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #346 holding.
  • GF Fund Management first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.